<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">REMIFENTANIL HYDROCHLORIDE</span><br/>(rem-i-fent'a-nil)<br/><span class="topboxtradename">Ultiva<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">narcotic (opiate) agonist</span>; <span class="classification">general anesthesia</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic, potent narcotic agonist analgesic similar to fentanyl. Rapidly metabolized, therefore respiratory depression is
         of shorter duration than fentanyl analogs when discontinued.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Used as the analgesic component of an anesthesia regime.</p>
<h1><a name="uses">Uses</a></h1>
<p>Analgesic during induction and maintenance of general anesthesia, as the analgesic component of monitored anesthesia care.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fentanyl analogs, epidural or intrathecal administration.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), lactation; head injuries, increased intracranial pressure; older adults, debilitated, poor-risk patients;
         COPD, other respiratory problems, bradyarrhythmia. Safety in labor and delivery has not been demonstrated. Safety and efficacy
         in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunct to Anesthesia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> &gt;2 y, 0.0252 mcg/kg/min or 1 mcg/kg injected over 3060 sec<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: See manufacturer's guidelines for reconstitution information and infusion rates.
         		
      </p>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Reduce starting doses by 50% for patients &gt;65 y. Base doses on ideal body weight for obese patients (&gt;30% over ideal
                     body weight).
                  </li>
<li>Clear IV tubing completely of the drug following discontinuation of remifentanil infusion to ensure that inadvertent administration
                     of the drug will not occur at a later time.
                  </li>
<li>Reconstituted solution is stable for 24 h at room temperature. Store vials of powder at 2°25° C (36°77°
                     F).
                  </li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Muscle rigidity, shivering. <span class="typehead">CNS:</span> Dizziness, headache. <span class="typehead">CV:</span> Hypotension, hypertension, bradycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea</span>, vomiting. <span class="typehead">Respiratory:</span> Respiratory depression, apnea. <span class="typehead">Skin:</span> Pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> potentiate effects; <span class="classification">mao inhibitors</span> may precipitate hypertensive crisis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 12 min. <span class="typehead"> Distribution:</span>  70% protein bound. <span class="typehead">Metabolism:</span> Hydrolyzed by nonspecific esterases in the blood and tissues. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 310 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs during postoperative period; observe for and immediately report any S&amp;S of respiratory distress or respiratory
            depression, or skeletal and thoracic muscle rigidity and weakness.
         </li>
<li>Monitor for adequate postoperative analgesia.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>